–

They found that when people with aphantasia try to conjure an image in their mind’s eye, the primary visual cortex – the part of the brain that processes picture-like visual information – is activated, but any images that are produced remain unconscious to the individual.

Published today in Current Biology, opens in a new window, the study, carried out by scientists at UNSW and South China Normal University, used a range of techniques to measure brain activity. Their findings challenge the existing theory that activity in the primary visual cortex directly produces conscious visual imagery.

“People with aphantasia actually do seem to have images of a sort, they remain too weak or distorted to become conscious or be measured by our standard measurement techniques,” says Prof. Joel Pearson, a co-author of the study based at UNSW’s School of Psychology, opens in a new window. “This may be because the visual cortex is wired differently, as evidenced by the data in this new study. This research not only deepens our understanding of the brain but also pushes the boundaries of how we think about imagination and consciousness.”

---

People with aphantasia still have a blueprint for mental imagery, even if they can’t consciously ‘see’ it.

A new biodegradable electrode stimulates brain repair by activating neural precursor cells, dissolving naturally after a week. This breakthrough could transform treatments for neurological disorders like stroke.

---

Summary: Researchers have developed a flexible, biodegradable electrode capable of stimulating neural precursor cells (NPCs) in the brain, offering a safer and more precise alternative for neural repair. The electrode dissolves naturally after seven days, eliminating the need for surgical removal while promoting tissue regeneration.

Made from FDA-approved materials, the device successfully increased NPC activity in preclinical models without causing significant inflammation or damage. This innovation could significantly expand treatment options for neurological disorders, which are a leading cause of disability worldwide.

Future developments aim to integrate drug and gene therapy delivery into the electrodes for enhanced therapeutic potential.

DLB is a common cause of dementia. It starts by the abnormal accumulation of the protein alpha-synuclein in the brain. This produces degeneration of the brain and causes problems with thinking, movement, and behavior. Eventually, the disease leads to dementia and death. Doctors use a imaging technique called FDG-PET to assess how the brain is affected in DLB. However, until now, there was no information on how these brain changes develop over time.

The study, led by Dr. Daniel Ferreira at the Department of Neurobiology, Care Sciences and Society, followed 35 patients with DLB, 37 patients with early-stage DLB (called prodromal DLB), and 100 healthy people from Mayo Clinic (USA), for an average of 3.8 years. The researchers found that brain degeneration starts early in prodromal DLB and worsens as the disease progresses.

“We discovered that people with prodromal DLB had faster degeneration in certain brain areas compared to healthy individuals,” said Dr. Ferreira.” This information is crucial for monitoring disease progression from early stages and planning clinical trials for new treatments.”

longitudinal FDG-PET metabolic change along the lewy body.

---

This case-control study assesses imaging and autopsy data from patients with dementia with Lewy bodies and probable dementia with Lewy bodies to investigate longitudinal change in 18F-fluorodeoxyglucose positron emission tomography.

Source: NUS

Researchers have uncovered novel insights into how brain function disruptions related to cerebrovascular disease (CeVD) interact with Alzheimer’s disease (AD) pathology to impact neurodegeneration and cognition in older adults.

Led by Associate Professor Juan Helen Zhou, Director of the Centre for Translational Magnetic Resonance Research, Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), the research team revealed a brain functional connectome phenotype that is related to multiple CeVD markers and contributes additively to cognitive decline and neurodegeneration alongside AD.

The brain’s response to emotional words is guided by neurotransmitters like dopamine and serotonin, shaping how we interpret language. Surprising new research shows even the thalamus is involved, bridging emotion and cognition.

---

Summary: Researchers have uncovered how neurotransmitters in the brain respond to the emotional content of language, shedding light on the intersection of emotion, cognition, and communication. Using advanced techniques, the team simultaneously measured dopamine, serotonin, and norepinephrine release in patients during exposure to emotionally charged words.

They found distinct patterns of neurotransmitter activity across brain regions like the thalamus and anterior cingulate cortex, challenging assumptions about their roles in emotional and linguistic processing.

These findings suggest that brain systems evolved for survival also support complex human functions like language interpretation. Validation in animal models confirmed these patterns, paving the way for future studies on decision-making and mental health.